0001193125-26-213321
SEC filingNet loss narrowed to $13.6M as Boundless Bio reduced operating expenses, but cash burn remains high with no near-term revenue.
Operating Income
Operating loss for the first quarter of 2026 was $14.5 million, compared to $17.3 million in the same period last year. The 16.5% improvement reflects the company's focus on cost management as it prioritizes its lead ecDTx candidate, BBI-940.
Net Income
Net loss narrowed to $13.6 million from $15.8 million in the prior-year quarter, a 14.0% reduction. The improvement was driven by lower operating expenses, partially offset by reduced interest income.
Diluted EPS
Diluted loss per share improved to $(0.60) from $(0.71), a 15.5% improvement, reflecting the lower net loss.
Liquidity and Capital Resources
General and Administrative Expenses
Outlook
Boundless Bio continues to advance its ecDTx platform, with no current commitments for additional collaborations. The company maintains discretion over the use of IPO proceeds, which are held in cash, cash equivalents, or short-term investments.